DeZwarteRidder schreef op 19 januari 2014 12:23:
FINANCIAL RESULTS
In the first half year of 2013, the Company generated revenue and other income of €4.9 million (H1 2012: €1.8 million). This increase results from the achievement of a milestone of US$ 5 million from our US partner Santarus for FDA acceptance for review of our BLA for Ruconest.
Product sales in H1 2013 amounted to €0.2 million compared to €0.8 million in H1 2012. The decline is due to a decrease in orders for Ruconest® from our EU partner Swedish Orphan Biovitrium (Sobi) which is a reflection of the underlying slow increase in EU sales. Costs of revenues amounted to € nil in H1 2013 compared to €0.8 million in H1 2012. In H1 2012, there was an inventory impairment of €2.2 million, while there were no impairments in H1 2013.